iOnctura
Developing precision small molecules to combat hard-to-treat tumors.
Geneve, Switzerland
28 employees
Series B
Total: $118.37M
Biotechnology, Health Care +2
General Information
Get notified when iOnctura moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track iOnctura
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
Switzerland Market
Biotechnology
About iOnctura
Taxonomy: biotech, cancer therapy, drug development, clinical-stage, cancer treatment, PI3Kδ inhibitor, autotaxin inhibitor, tumor survival pathways, immunotherapy, precision medicine, oncology, investors, clinical trial, innovation, targeted therapy
Funding Rounds & Investors (9)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series B | €80.00M | 7 |
|
20 Jun 2024 |
| Grant | €367.73K | 1 | KWF Kankerbestrijding | 15 May 2024 |
| Grant | Unknown | 2 |
|
03 May 2023 |
| Venture Round | €15.00M | 1 |
|
20 Dec 2022 |
| Grant | €2.50M | 1 |
|
20 Dec 2022 |
Latest News
View All
iOnctura Alternatives & Competitors
Developing inobrodib (CCS1477), first-in-class p300/CBP inhibitor to treat specific cancers.
Teon is a clinical company targeting metabolic signaling pathways and pioneering the development of...
The Path to Better
FAQ About iOnctura
Don't just browse. Track.
Signal Tracker monitors iOnctura and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.